Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer

doi:10.1016/j.ygyno.2010.05.032

Gynecologic Oncology

Volume 118, Issue 3, September 2010, Pages 237-243

https://doi.org/10.1016/j.ygyno.2010.05.032 Get rights and content

Abstract

Objectives

There is a need for identification of new biomarkers improving our understanding, diagnosis, and follow-up of ovarian cancer. Growth differentiation factor-15 (GDF-15) is a member of the transforming growth factor-β superfamily, and GDF-15 overexpression has been found in several cancer forms but has not been explored in ovarian cancer. The aim of the study was to explore preoperative plasma concentration and tissue expression of growth differentiation factor (GDF)-15 in ovarian tumors.

Methods

GDF-15 concentration was measured by immunoradiometric assay in plasma samples from patients with invasive ovarian cancer (n = 125), borderline ovarian tumor (BOT, n = 43), and benign ovarian tumor (n = 144), from healthy women (n = 40), as well as in effusion samples (n = 44) from women with advanced ovarian cancer. Sections of ovarian carcinoma (n = 20), BOT (n = 9), and cystadenoma (n = 7) were immunostained for GDF-15.

Results

Median plasma GDF-15 concentration was elevated in ovarian cancer as compared to healthy controls and women with benign ovarian tumors or BOT (p < 0.001). GDF-15 plasma concentration correlated inversely with survival time and was an independent predictor of survival, after correction for FIGO stage and age (p = 0.01). GDF-15 protein was cytoplasmatically expressed in serous tumor cells and detectable in high concentrations in effusion samples.

Conclusion

GDF-15 emerges as a new potential biomarker in ovarian cancer.

Introduction

Ovarian cancer has the highest mortality rate of all gynecologic cancers and is the fifth leading cause for female cancer-related death. Circulating CA 125 is currently the biomarker commonly used, but its value is limited, especially in the early stages of disease, where up to 50% of women have concentrations within normal range [1]. Because of the current poor prognosis for women with ovarian cancer, there is a need for identification of new biomarkers improving our understanding, diagnosis, and follow-up of ovarian cancer.

Growth differentiation factor-15 (GDF-15) is a distant member of the transforming growth factor (TGF)-β superfamily, also named macrophage-inhibitory cytokine-1 (MIC-1), and was originally identified in an activated macrophage cell line [2]. The major biological role of GDF-15 is uncertain, but GDF-15 is suggested to regulate a wide variety of physiologic processes, including growth inhibition, induction of apoptosis, cell detachment, and tumor invasiveness [3]. In healthy individuals, GDF-15 is weakly expressed in most tissues, with the notable exception of the placenta [4]. Accordingly, very high circulating concentrations of GDF-15 can be measured in pregnant women in their second and third trimesters [5], [6]. While the function of GDF-15 during pregnancy remains unknown, low serum concentrations of GDF-15 have been found to indicate an increased risk of miscarriages [7]. We have recently demonstrated augmented circulating concentrations of GDF-15 in pregnancies complicated by preeclampsia or diabetes mellitus, conditions associated with an augmented risk of cardiovascular disease [6]. Along that line, elevated circulating concentrations of GDF-15 have been associated with an increased risk of future cardiovascular events in apparently healthy elderly women [8].

In contrast to its low expression under baseline conditions, GDF-15 is strongly increased in pathological situations associated with inflammation, acute tissue injury, and malignancy [9], [10], [11], [12] and is induced rapidly by cytokines [2], [4], [13]. GDF-15 overexpression has been found in prostate, thyroid, pancreatic, and colonic cancers as well as in malignant melanomas [3], [11], [14], [15], [16], [17], [18].

As GDF-15 has a potential clinical value in other malignancies, the aim of our study was to explore the role of GDF-15 as a potential biomarker in ovarian cancer, relating plasma concentrations to clinicopathologic parameters and survival time. We also wanted to explore ovarian tumor and effusion expression of GDF-15.

Section snippets

Study subjects

Preoperative fasting EDTA plasma samples were collected from women with primary ovarian cancer (n = 125), borderline ovarian tumor (BOT, n = 43), and benign ovarian tumors (n = 144) operated on at Oslo University Hospital, Ulleval, during 2003–2009. No patients had a prior diagnosis of cancer or had received chemotherapy or surgery for the present disease. Fasting EDTA plasma samples were also collected from 20 premenopausal and 20 postmenopausal healthy women, working at the same hospital. Also, 42

Results

Clinical characteristics are presented in Table 1. As expected, preoperative risk-of-malignancy index (RMI) [22], [23], calculated as the product of an ultrasound adnexal tumor score grading (1–3), menopausal state grading (1–3), and CA 125 serum concentration (U/mL), differed significantly as expected between the three patient groups with ovarian tumors (Table 1, p < 0.001). Fig. 1A shows the individual GDF-15 plasma concentrations for all patient groups and healthy controls.

Discussion

Our study demonstrates that the preoperative plasma concentration of GDF-15 is elevated in women with ovarian cancer as compared to healthy pre- and postmenopausal women and women with benign adnexal tumors or BOT.

A major finding of the study was that preoperative GDF-15 predicted survival time for women with ovarian cancer, independent of stage and age. Elevated GDF-15 also predicts cardiovascular deaths in patients with established cardiovascular disease [24], [25], [26] as well as predicts

Conflict of interest statement

Drs. Kempf and Wollert have filed a patent and have a contract with Roche Diagnostics to develop a GDF-15 assay for cardiovascular applications. No products/companies are discussed in the article in which any author has an interest. Therefore, there are no potential conflicts of interest.

Acknowledgments

We are grateful for help in patient recruitment and biobank assistance from Lise Levy and Elin Ødegaard, both Oslo University Hospital.

References (35)

L.N. Lawton et al.
Identification of a novel member of the TGF-beta superfamily highly expressed in human placenta
Gene
(5-12-1997)
S. Tong et al.
Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage
Lancet
(10-1-2004)
D.A. Brown et al.
Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case–control study
Lancet
(22-6-2002)
V.M. Paralkar et al.
Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family
J Biol Chem
(29-5-1998)
E. Odegaard et al.
Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary
Am J Obstet Gynecol
(2008)
E. Odegaard et al.
Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary
Am J Obstet Gynecol
(2008)
T. Kempf et al.
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure
J Am Coll Cardiol
(11-9-2007)
P.X. Li et al.
Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression
J Biol Chem
(30-6-2000)
D.L. Clarke-Pearson
Clinical practice. Screening for ovarian cancer
N Engl J Med
(9-7-2009)
M.R. Bootcov et al.
MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily
Proc Natl Acad Sci U S A
(14-10-1997)

D.A. Brown et al.

Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis

Clin Cancer Res

(1-1-2006)

A.G. Moore et al.

The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women

J Clin Endocrinol Metab

(2000)

M. Sugulle et al.

Circulating and placental growth-differentiation factor 15 in preeclampsia and in pregnancy complicated by diabetes mellitus

Hypertension

(2009)

J.B. Welsh et al.

Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum

Proc Natl Acad Sci U S A

(18-3-2003)

W.D. Fairlie et al.

MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation

J Leukoc Biol

(1999)

T. Liu et al.

Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells

Cancer Res

(15-8-2003)

T.A. Zimmers et al.

Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury

Shock

(2005)

Cited by (68)

GPX3 supports ovarian cancer tumor progression in vivo and promotes expression of GDF15
2024, Gynecologic Oncology
We previously reported that high expression of the extracellular glutathione peroxidase GPX3 is associated with poor patient outcome in ovarian serous adenocarcinomas, and that GPX3 protects ovarian cancer cells from oxidative stress in culture. Here we tested if GPX3 is necessary for tumor establishment in vivo and to identify novel downstream mediators of GPX3's pro-tumorigenic function.
GPX3 was knocked-down in ID8 ovarian cancer cells by shRNA to test the role of GPX3 in tumor establishment using a syngeneic IP xenograft model. RNA sequencing analysis was carried out in OVCAR3 cells following shRNA-mediated GPX3 knock-down to identify GPX3-dependent gene expression signatures.
GPX3 knock-down abrogated clonogenicity and intraperitoneal tumor development in vivo, and the effects were dependent on the level of GPX3 knock-down. RNA sequencing showed that loss of GPX3 leads to decreased gene expression patterns related to pro-tumorigenic signaling pathways. Validation studies identified GDF15 as strongly dependent on GPX3. GDF15, a member of the TGF-β growth factor family, has known oncogenic and immune modulatory activities. Similarly, GPX3 expression positively correlated with pro-tumor immune cell signatures, including regulatory T-cell and macrophage infiltration, and displayed significant correlation with PD-L1 expression.
We show for the first time that tumor produced GPX3 is necessary for ovarian cancer growth in vivo and that it regulates expression of GDF15. The immune profile associated with GPX3 expression in serous ovarian tumors suggests that GPX3 may be an alternate marker of ovarian tumors susceptible to immune check-point inhibitors.
Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study
2023, Journal of Thrombosis and Haemostasis
Patients with cancer are at increased risk of venous thromboembolism (VTE) and arterial thromboembolic/thrombotic events (ATEs). Growth differentiation factor-15 (GDF-15) improves cardiovascular risk assessment, but its predictive utility in patients with cancer remains undefined.
To investigate the association of GDF-15 with the risks of VTE, ATE, and mortality in patients with cancer and its predictive utility alongside established models.
The Vienna Cancer and Thrombosis Study (CATS)—a prospective, observational cohort study of patients with newly diagnosed or recurrent cancer—which was followed for 2 years, served as the study framework. Serum GDF-15 levels at study inclusion were measured, and any association with VTE, ATE, and death was determined using competing risk (VTE/ATE) or Cox regression (death) modeling. The added value of GDF-15 to established VTE risk prediction models was assessed using the Khorana and Vienna CATScore.
Among 1531 included patients with cancer (median age, 62 years; 53% men), median GDF-15 levels were 1004 ng/L (IQR, 654-1750). Increasing levels of GDF-15 were associated with the increased risks of VTE, ATE, and all-cause death ([subdistribution] hazard ratio per doubling, 1.16 [95% CI, 1.03-1.32], 1.30 [95% CI, 1.11-1.53], and 1.57 [95% CI, 1.46-1.69], respectively). After adjustment for clinically relevant covariates, the association only prevailed for all-cause death (hazard ratio, 1.21; 95% CI, 1.10-1.33) and GDF-15 did not improve the performance of the Khorana or Vienna CATScore.
GDF-15 is strongly associated with survival in patients with cancer, independent of the established risk factors. While an association with ATE and VTE was identified in univariable analysis, GDF-15 was not independently associated with these outcomes and failed to improve established VTE prediction models.
Screening study of anti-emetics to improve GDF15-induced malaise and anorexia: Implications for emesis control
2023, Physiology and Behavior
Considerable preclinical and clinical attention has focused on the food intake and body weight suppressive effects of growth differentiation factor 15 (GDF15) and its elevated blood levels as a consequence of disease states and disease treatment therapeutics. We have previously reported that exogenous administration of GDF15 induces anorexia through nausea and emesis in multiple species. Importantly, GDF15 signaling as a meditator of chemotherapy-induced anorexia and emesis has recently been demonstrated in both murine and nonhuman primate models. The mechanism, however, by which GDF15 induces malaise and the utility of existing therapeutic targets to counteract its effects remain largely unknown. Using a dose of GDF15 that mimics stimulated levels following chemotherapy administration and reliably induces malaise, we sought to screen anti-emetics that represent distinct pharmacotherapeutic classes hypothesized to reduce GDF15-induced effects in rats. Strikingly, our results showed that none of the tested compounds were effective at preventing GDF15-induced malaise. These results illustrate the complexity of GDF15 signaling mechanism and may have important implications for medical conditions characterized by elevated GDF15 levels and incomplete symptom control, such as chemotherapy-induced nausea and vomiting.
Mass Spectrometry–Based Proteomics of Epithelial Ovarian Cancers: A Clinical Perspective
2023, Molecular and Cellular Proteomics
Increasing proteomic studies focused on epithelial ovarian cancer (EOC) have attempted to identify early disease biomarkers, establish molecular stratification, and discover novel druggable targets. Here we review these recent studies from a clinical perspective. Multiple blood proteins have been used clinically as diagnostic markers. The ROMA test integrates CA125 and HE4, while the OVA1 and OVA2 tests analyze multiple proteins identified by proteomics. Targeted proteomics has been widely used to identify and validate potential diagnostic biomarkers in EOCs, but none has yet been approved for clinical adoption. Discovery of proteomic characterization of bulk EOC tissue specimens has uncovered a large number of dysregulated proteins, proposed new stratification schemes, and revealed novel targets of therapeutic potential. A major hurdle facing clinical translation of these stratification schemes based on bulk proteomic profiling is intra-tumor heterogeneity, namely that single tumor specimens may harbor molecular features of multiple subtypes. We reviewed over 2500 interventional clinical trials of ovarian cancers since 1990 and cataloged 22 types of interventions adopted in these trials. Among 1418 clinical trials which have been completed or are not recruiting new patients, about 50% investigated chemotherapies. Thirty-seven clinical trials are at phase 3 or 4, of which 12 focus on PARP, 10 on VEGFR, 9 on conventional anti-cancer agents, and the remaining on sex hormones, MEK1/2, PD-L1, ERBB, and FRα. Although none of the foregoing therapeutic targets were discovered by proteomics, newer targets discovered by proteomics, including HSP90 and cancer/testis antigens, are being tested also in clinical trials. To accelerate the translation of proteomic findings to clinical practice, future studies need to be designed and executed to the stringent standards of practice-changing clinical trials. We anticipate that the rapidly evolving technology of spatial and single-cell proteomics will deconvolute the intra-tumor heterogeneity of EOCs, further facilitating their precise stratification and superior treatment outcomes.
Single nuclei RNA sequencing of the rat AP and NTS following GDF15 treatment
2022, Molecular Metabolism
Growth differentiation factor 15 (GDF15) is known to play a role in feeding, nausea, and body weight, with action through the GFRAL-RET receptor complex in the area postrema (AP) and nucleus tractus solitarius (NTS). To further elucidate the underlying cell type-specific molecular mechanisms downstream of GDF15 signaling, we used a single nuclei RNA sequencing (snRNAseq) approach to profile AP and NTS cellular subtype-specific transcriptomes after systemic GDF15 treatment.
AP and NTS micropunches were used for snRNAseq from Sprague Dawley rats 6 h following GDF15 or saline injection, and Seurat was used to identify cellular subtypes and cell type-specific alterations in gene expression that were due to the direct and secondary effects of systemic GDF15 treatment.
Using the transcriptome profile of ∼35,000 individual AP/NTS nuclei, we identified 19 transcriptomically distinct cellular subtypes, including a single population Gfral and Ret positive excitatory neurons, representing the primary site of action for GDF15. A total of ∼600 cell type-specific differential expression events were identified in neurons and glia, including the identification of transcriptome alterations specific to the direct effects of GDF15 in the Gfral-Ret positive excitatory neurons and shared transcriptome alterations across neuronal and glial cell types. Downstream analyses identified shared and cell type-specific alterations in signaling pathways and upstream regulatory mechanisms of the observed transcriptome alterations.
These data provide a considerable advance in our understanding of AP and NTS cell type-specific molecular mechanisms associated with GDF15 signaling. The identified cellular subtype-specific regulatory mechanism and signaling pathways likely represent important targets for future pharmacotherapies.
Growth differentiation factor-15 promotes immune escape of ovarian cancer via targeting CD44 in dendritic cells
2021, Experimental Cell Research
Citation Excerpt :
The results on the biological functions of GDF-15 revealed that GDF-15 expression in the ovarian tissue was higher in the ovarian cancer tissue than in the normal ovarian tissue (Fig. 1 A). Same result was obtained with the GDF-15 level in the serum (Fig. 1 B), which was consistent with the results published in a previous report [26], although some differences were observed in the concentration. The serum GDF-15 level in our experiment was low, which might be related to the detection method, the kit used, the treatment and preservation of the samples and individual differences.
Immune escape is the main cause of the low response rate to immunotherapy for cancer, including ovarian cancer. Growth differentiation factor-15 (GDF-15) inhibits immune cell function. However, only few reports described the mechanism. Therefore, the aim of this study was to investigate the mechanism of immune escape regulated by GDF-15 in ovarian cancer. Ovarian cancer patients and healthy women were enrolled in this study. Immunohistochemistry and ELISA were performed to measure GDF-15 expression. Immunoprecipitation combined with mass spectrometry, surface plasmon resonance, and co-immunoprecipitation assay were used to evaluate the interaction between GDF-15 and the surface molecules of DCs. Immunofluorescence analysis, flow cytometry and transwell assay were used to evaluate additional effects of GDF-15 on DCs. The results showed that GDF-15 expression was higher in the ovarian cancer patients compared to that in the healthy women. The TIMER algorithm revealed that highly GDF-15 expression is associated with immune DC infiltration in immunoreactive high-grade serous carcinoma. A further study showed that GDF-15 suppressed DCs maturation, as well as IL-12p40 and TNF-α secretion, the length and number of protrusions and the migration. More importantly, CD44 in the surface of DCs interacted with GDF-15. The overexpression of CD44 in DCs resulted in the suppression of the inhibitory effect of GDF-15 on the length and number of DC synapses. In DCs overexpressing CD44 the inhibition of GDF-15 on the expression of CD11c, CD83 and CD86 was decreased, while in DCs with a knockdown of CD44 the inhibition was further enhanced. Knockdown of CD44 in DCs enhanced the inhibitory effect of GDF-15 on DC migration, while the overexpression of CD44 inhibited the inhibitory effect of GDF-15 on DC migration. In conclusion, the present study suggested that GDF-15 might facilitate ovarian cancer immune escape by interacting with CD44 in DCs to inhibit their function.

View all citing articles on Scopus

View full text

Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer

Abstract

Objectives

Methods

Results

Conclusion

Introduction

Section snippets

Study subjects

Results

Discussion

Conflict of interest statement

Acknowledgments

Gene

Lancet

Lancet

J Biol Chem

Am J Obstet Gynecol

Am J Obstet Gynecol

J Am Coll Cardiol

J Biol Chem

Clinical practice. Screening for ovarian cancer

N Engl J Med

MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily

Proc Natl Acad Sci U S A

Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis

Clin Cancer Res

The transforming growth factor-ss superfamily cytokine macrophage inhibitory cytokine-1 is present in high concentrations in the serum of pregnant women

J Clin Endocrinol Metab

Circulating and placental growth-differentiation factor 15 in preeclampsia and in pregnancy complicated by diabetes mellitus

Hypertension

Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum

Proc Natl Acad Sci U S A

MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation

J Leukoc Biol

Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells

Cancer Res

Growth differentiation factor-15/macrophage inhibitory cytokine-1 induction after kidney and lung injury

Shock